The MarketReader Minute
💊Nuvalent Up on Trial Data Presentation, Gilead Gains with HIV Program Progress, Argenx and Zai Lab Rise on China Approval | Biotech Sector Insights
Gilead highlighted advancements in their HIV programs at AIDS 2024 event which could have influenced its stock performance. Amgen reported increased options trading ahead of an earnings announcement and Vertex extended collaboration for precision medicine development using human genetics.